November 30, 1998
PALADIN PURCHASES MOI-STIR TRADEMARK FROM SOLVAY PHARMA INC.

August 20, 1998
PALADIN ANNOUNCES SIGNING OF BINDING LETTER OF INTENT WITH ACCESS PHARMACEUTICALS.

July 31, 1998
PALADIN LABS ANNOUNCES THE APPOINTMENT OF 3 NEW BOARD MEMBERS.

July 31, 1998
PALADIN LABS COMPLETES A $13.9 MILLION PRODUCT ACQUISITION AND A $6 MILLION PRIVATE PLACEMENT.

June 11, 1998
PALADIN LABS RECEIVES TPD APPROVAL FOR SALE OF PMS-SELEGILINE.

May 29, 1998
PALADIN LABS SIGNS CONDITIONAL LETTER OF INTENT WITH THE ROYAL BANK CAPITAL CORPORATION AND BIOCAPITAL INC. FOR $4 MILLION OF EQUITY FINANCING AT $4.30 SHARE.

April 23, 1998
ACQUISITION OF PHARMACEUTICAL PRODUCTS AND CANADIAN DISTRIBUTION RIGHTS FROM PHARMASCIENCE.

March 20, 1998
PALADIN ACQUIRES THE EXCLUSIVE CANADIAN LICENSE FOR SIALOR^® FROM SOLVAY PHARMA INC.